Eli Lilly SG&A decreased by 6.3% to $2.93B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.9%, from $2.47B to $2.93B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 14.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.58B | $1.59B | $1.56B | $1.63B | $1.61B | $1.64B | $1.75B | $1.93B | $1.80B | $1.93B | $1.95B | $2.12B | $2.10B | $2.42B | $2.47B | $2.75B | $2.74B | $3.13B | $2.93B |
| QoQ Change | — | -6.4% | +0.9% | -2.1% | +4.3% | -0.7% | +1.8% | +6.5% | +10.1% | -6.3% | +6.7% | +1.4% | +8.5% | -0.8% | +15.5% | +1.8% | +11.5% | -0.4% | +14.3% | -6.3% |
| YoY Change | — | — | — | — | -3.6% | +2.3% | +3.2% | +12.3% | +18.5% | +11.8% | +17.2% | +11.6% | +10.0% | +16.4% | +25.9% | +26.4% | +30.0% | +30.5% | +29.1% | +18.9% |
Range$1.56B – $3.13B
CAGR+12.4%
Avg YoY Growth+16.3%
Median YoY Growth+16.8%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $2.47B | $2.75B | $2.74B | $3.13B | $2.93B |
| Total | $2.47B | $2.75B | $2.74B | $3.13B | $2.93B |
SG&A at Other Companies
Frequently Asked Questions
- What is Eli Lilly's sg&a?
- Eli Lilly (LLY) reported sg&a of $2.93B in Q1 2026.
- How has Eli Lilly's sg&a changed year-over-year?
- Eli Lilly's sg&a increased by 18.9% year-over-year, from $2.47B to $2.93B.
- What is the long-term trend for Eli Lilly's sg&a?
- Over 4 years (2021 to 2025), Eli Lilly's sg&a has grown at a 14.6% compound annual growth rate (CAGR), from $6.43B to $11.09B.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.